Skip to main content
. 2021 Apr 1;14(4):305. doi: 10.3390/ph14040305

Table 2.

Clinical studies on EGb 761® in patients with MCI, vMCI, and dementia.

Inclusion Criteria Treatment Groups Results References
EGb 761® in vMCI, MCI and dementia prevention
Non-demented patients EGb 761® or Piracetam and placebo, data collected on cognitive function over a period of twenty years Patients treated with EGb 761® highlighted a slower cognitive impairment than in Piracetam group. Moreover, EGb 761® patients showed a significant reduction of psychotropic drugs assumption. [90]
Patients with very mild cognitive impairment and low functioning EGb 761® (240 mg/die) or placebo, for 12 weeks Patients treated with EGb 761® showed an improvement of memory performances, measured through Wechsler Memory Scale III (human face recognition in pictures) and a significant attention improvement, by using the Vienna Test System Work Performance Series (a computerized math test to keep concentration). [91]
EGb 761® MCI, neurocognitive deficit and dementia
Patients with amnesic MCI EGb 761® (240 mg/die) or placebo, for 24 weeks Patients treated with EGb 761® showed improvement in all the neuropsychiatric symptoms, measured through Neuropsychiatrics Inventory (NPI) sympoms. [94]
Patients with normal cognitive function or MCI EGb 761® (240 mg/die) or placebo, patients were evaluated every 6 months This study didn’t demonstrate any significant benefit to prevent dementia development with EGb 761® treatment versus placebo. [95]
Outpatients with mild to moderate dementia (AD or VaD) EGb 761® (240 mg/die) or placebo, for 24 weeks Patients treated with EGb 761® demonstrated neuro psychiatric improvement for Neuropsychiatric Inventory (NPI) symptoms. [96]
Outpatients 24-week with mild to moderate dementia (Alzheimer’s disease or vascular dementia) associated with neuropsychiatric symptoms EGb 761® (240 mg/die) or placebo, for 24 weeks Treatment with EGb 761® led to a significant and clinically relevant improvement in patients’ cognition, psychopathology, functional measures and quality of life. [97]